Following AstraZeneca's clinical trial failure, investor sentiment has turned negative, leading Stifel to cut the price target for Olema Pharmaceuticals.
1 report, 1 independent
Updated Sep 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Following AstraZeneca's clinical trial failure, investor sentiment has turned negative, leading Stifel to cut the price target for Olema Pharmaceuticals.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Olema Pharmaceuticals (United States)
company in San Francisco, United States
Nothing else this week.
-
AstraZeneca
British-Swedish pharmaceutical company